Skip to main content
Fig. 3 | Orphanet Journal of Rare Diseases

Fig. 3

From: Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease

Fig. 3

Treatment-effect development over time under the delayed-start design. The delayed-start design (early-start group versus delayed-start group) is compared with the standard parallel design (early-start group versus placebo group) in terms of a immediate treatment effects, b developing treatment effects reaching complete efficacy and c developing treatment effects with complete efficacy without reaching complete efficacy

Back to article page